[Prevention of side effects of specific chemotherapy in patients with pulmonary tuberculosis].
Data are given related to a combined examination of 168 pulmonary tuberculosis patients in whom immunomodulating T-activin and levamisole chemotherapy was carried out in 40 subjects. In tuberculosis patients with significantly abnormal parameters of the immunity T-system, side effects of the antituberculosis drugs developed in 67.7%, while in those who were subjected to a general scheme of treatment with inclusion of the immunomodulating drugs in only 17.5%. T-activin was found to be highly effective in preventing side effects of the antituberculosis drugs. A diverse influence of the immunity modulating drugs on some T-lymphocyte classes was registered, which is essential in choosing the suitable modulator and regimen of its use.
Batian
A N
AN
Abramovskaia
A K
AK
Batian
O N
ON
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology; D007978:Levamisole / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D013949:Thymus Extracts / Q000008:administration & dosage*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D000995:Antitubercular Agents; D010455:Peptides; D013949:Thymus Extracts; D007978:Levamisole; C036191:T-activin
Preduprezhdenie razvitiia pobochnogo deĭstviia spetsificheskoĭ khimioterapii u bol'nykh tuberkulezom legkikh.